Fosinopril Actavis

Quick links

Choose a section

Quick links to important sections

Advertisements

Fosinopril Actavis

Advertisements
Advertisements

Overview of Fosinopril Actavis

What is Fosinopril Actavis?

Fosinopril Actavis is a medication belonging to the class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It is primarily used in the management of cardiovascular conditions, specifically hypertension (high blood pressure) and heart failure.

Mechanism of Action

The active substance, fosinopril sodium, is a prodrug that is converted in the body to its active form, fosinoprilat. It works by inhibiting the enzyme responsible for the production of angiotensin II, a potent substance that causes blood vessels to narrow. By blocking this process, the medication helps blood vessels to relax and widen, which facilitates easier blood flow and reduces the workload on the heart.

Clinical Applications

  • Hypertension: It is used to lower elevated blood pressure. Maintaining blood pressure within a normal range helps reduce the long-term risk of cardiovascular events.
  • Heart Failure: It is used as part of a management plan for patients with symptomatic heart failure. In this context, it helps improve the heart's pumping efficiency and may reduce the need for hospitalization related to heart condition progression.

Physical Characteristics

Fosinopril Actavis is typically produced as oral tablets available in different strengths, such as 10 mg and 20 mg. These tablets contain the active ingredient fosinopril sodium along with various inactive excipients used to form the tablet structure.

Advertisements

What side effects are possible with Fosinopril Actavis?

Possible Side Effects and Safety Information

The safety profile of Fosinopril Actavis is established by government regulatory documents, detailing known adverse reactions and necessary precautions. This information is organized by the frequency and type of reaction observed during clinical studies.

Serious Safety Risks and Contraindications

The most significant and life-threatening adverse reaction documented is angioedema, which involves rapid and severe swelling of the face, limbs, lips, tongue, glottis, or larynx. Immediate medical attention is required if this occurs. Fosinopril is contraindicated in the second and third trimesters of pregnancy due to the risk of injury or death to the developing fetus (fetal toxicity). It is also contraindicated in patients with a history of angioedema related to previous ACE inhibitor treatment.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to their reported frequency:

  • Common (may affect up to 1 in 10 people): Upper respiratory tract infection, pharyngitis, cough, headache, dizziness, fatigue, nausea, vomiting, diarrhea, abdominal pain, and chest pain.
  • Uncommon (may affect up to 1 in 100 people): Palpitations, chest pain (angina pectoris), rhythm disturbances, hypotension (low blood pressure), syncope (fainting), dyspnoea (shortness of breath), rash, and pruritus (itching).

Caution in Specific Populations

Use requires particular caution and monitoring in patients with pre-existing renal impairment (kidney disease) or hepatic impairment (liver disease), as these conditions can affect how the body processes the medication. Hypotension and syncope are more likely to occur at the start of therapy, especially in patients who are already fluid or salt depleted.

Advertisements

Overdose and Emergency Response

Overdose: When to Seek Help

The most common presentation of an overdose with Fosinopril Actavis (fosinopril) is likely to be severe hypotension (extremely low blood pressure). As an Angiotensin-Converting Enzyme (ACE) inhibitor, excessive intake primarily affects the cardiovascular system, resulting in a potentially dangerous fall in blood pressure.

Clinical Manifestations and Risk Factors

Symptoms associated with severe hypotension include feeling dizzy or fainting. Although human overdose cases are rarely reported, the primary risk is associated with an acute, excessive intake of the medicine. Ingestion by children by accident is specifically noted as a circumstance requiring immediate medical assessment.

Required Emergency Action

If an overdose is suspected, or if a child has accidentally taken the medicine, urgent medical attention is required immediately. You must telephone a doctor, Poison Control Center, or go to the Emergency Department at your nearest hospital right away, even if the person currently shows no signs of discomfort.

Fosinoprilat, the active metabolite, is known to be poorly removed from the body by common dialysis procedures such as hemodialysis and peritoneal dialysis, underscoring the need for timely clinical management.

Advertisements

Therapeutic Uses of Fosinopril Actavis

What Fosinopril Actavis Treats: Main Uses and Benefits

Fosinopril Actavis is commonly used for the long-term management of essential hypertension (high blood pressure) and in the management of symptomatic heart failure. The primary therapeutic domains include chronic management of elevated blood pressure and providing support in conditions where functional stability has been affected.

Supportive Relief and Therapeutic Domains

This medication is applied in situations involving certain distressing symptoms, where it helps address symptom clusters that may become intense or disruptive. The medication supports patients during difficult episodes by easing distress related to cardiac strain and assists with managing organ-specific functional stress. Common conditions for which it is prescribed include essential hypertension, symptomatic heart failure, and providing support for high-risk patients like those with hypertension and diabetes. Therapy may assist with maintaining functional stability and contribute to improved day-to-day comfort during symptomatic periods.

This therapeutic application is relevant in conditions marked by increased physiological stress, often stemming from chronic circulatory conditions, and contributes to improved comfort during periods of heightened symptoms such as excessive fatigue, shortness of breath upon exertion (dyspnea), and fluid retention (edema).


Therapeutic Support Summary

Domain Benefit Context
Hypertension Assists with general well-being Chronic management of vascular stress
Heart Failure Helps manage overall symptom load Support for daily functioning
Diabetic Support Support for functional stability Relevant for organ-specific functional stress

Regulatory References

  1. NIH MedlinePlus overview on Fosinopril
Advertisements

Eligibility and Restrictions for Use

Fosinopril Actavis (fosinopril sodium) is strictly governed by regulatory rules that define who can and cannot use the medicine. Eligibility is determined by patient history, physiological state, and concurrent medications.

Absolute Prohibitions

The medicine is contraindicated and must not be used by several populations. These absolute exclusions include women in their second or third trimesters of pregnancy due to the risk of fetal injury. It is also prohibited for patients with a documented history of angioedema (severe swelling) related to previous use of any Angiotensin-Converting Enzyme (ACE) inhibitor.

A further contraindication exists for concomitant use alongside Aliskiren in patients with Diabetes Mellitus, and with Sacubitril/Valsartan without observing a mandatory 36-hour wash-out period.

Age and Organ Restrictions

Use is generally established for adults and for pediatric patients aged 6 to 16 years for hypertension. The medicine is not recommended for children under 6 years of age as safety and efficacy have not been established. Use requires caution and monitoring in patients with severe hepatic impairment or renal impairment due to reduced clearance of the active metabolite. It is also not recommended for women who are breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fosinopril Actavis (fosinopril) can interact with several medicinal products and substances, necessitating careful review by a healthcare provider.

Contraindicated Combinations

Dual blockade of the Renin-Angiotensin System (RAS): Co-administration with Sacubitril/Valsartan is contraindicated; Fosinopril must not be started within 36 hours of the last dose of this combination. Use with Aliskiren is also contraindicated in patients with diabetes or moderate-to-severe kidney impairment (GFR < 60 mL/min/1.73 m^2). The use of ACE inhibitors is also restricted during certain procedures like LDL-apheresis.

Clinically Significant Interactions

Interacting Substance/Class Potential Outcome
Potassium-Sparing Diuretics/Potassium Supplements Increased risk of hyperkalemia (high potassium levels).
Lithium Reduced lithium elimination, leading to increased serum lithium levels and toxicity risk.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Reduced blood pressure-lowering effect; risk of kidney function deterioration, especially in the elderly.
mTOR Inhibitors (e.g., Temsirolimus, Everolimus) Increased risk of angioedema (swelling).
Antacids (Aluminum/Magnesium) Reduced absorption of Fosinopril. Dosing must be separated by 2 hours.

Fosinopril can potentiate the effects of Antidiabetics (insulin and oral agents), increasing the risk of hypoglycemia. Unlike some medications, the absorption of Fosinopril is generally not affected by food.

Advertisements

Mechanism of Action

Fosinopril is a phosphorus-containing ester prodrug that undergoes rapid hydrolysis, primarily in the gastrointestinal mucosa and liver, to form its active metabolite, fosinoprilat. Fosinoprilat functions as a competitive inhibitor of the enzyme angiotensin-converting enzyme (ACE), also known as kininase II. ACE, a metalloprotease, is a component of the renin-angiotensin-aldosterone system (RAAS).

Fosinoprilat occupies the active site of ACE, preventing the enzymatic cleavage of circulating angiotensin I (ATI) to the potent vasoconstrictor, angiotensin II (ATII). This molecular interaction leads to a diminished concentration of ATII in the plasma and tissues. The intracellular consequence of decreased ATII includes the reduced stimulation of the AT1 receptor on vascular smooth muscle cells and the attenuation of aldosterone secretion from the adrenal cortex.

Furthermore, ACE is responsible for the enzymatic deactivation of the vasodilator peptide, bradykinin. Inhibition of ACE by fosinoprilat reduces bradykinin degradation, leading to increased local concentrations of bradykinin. The system-level physiological consequences are a decrease in peripheral vascular resistance due to arterial and venous dilation, and enhanced sodium and water excretion secondary to lower aldosterone levels.

Advertisements

Dosage and Administration Information

Administration Scope

Instruction Entity Official Regulatory Guideline
Route of administration Oral administration only, as a tablet to be swallowed.
Dosing schedule Hypertension: The standard initial dose is 10 mg once daily. The typical maintenance range is 10 mg to 40 mg once daily.
Heart Failure: The standard initial dose is 10 mg once daily, with a maximum target dose of 40 mg daily.
Timing in relation to meals May be taken with or without food, as absorption is not significantly affected. If an antacid containing aluminum or magnesium is taken, it must be administered at least two hours before or two hours after the Fosinopril dose.
Age-group administration Pediatric use is confined to children ≥ 6 years of age. Dosing is weight-based for children < 50 kg (e.g., 0.1 mg/kg/day), and 5 mg to 10 mg daily for children ≥ 50 kg.
Missed-dose rules If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, the missed dose should be skipped; do not take a double dose to compensate.
Special procedural conditions The initial dose for Heart Failure or for patients who are volume-depleted requires close medical supervision for several hours. A lower starting dose of 5 mg is recommended for Heart Failure patients with moderate to severe renal impairment.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral.
Frequency pattern Daily (once daily, though split dosing may be considered if trough blood pressure response is insufficient).
Use-context constraints Requires titration; dose separation from specific antacids; dose modification for certain patient populations.

Resulting Procedural Structure

Official step sequence:

  • Initiate treatment at the low starting dose, adjusting to 5 mg for certain high-risk patient groups or those with severe kidney impairment in Heart Failure.
  • Administer the dose orally once daily, adhering to the two-hour separation rule from aluminum/magnesium antacids.
  • Titrate the dose gradually over several weeks to reach the approved maintenance dose, based on the blood pressure response and patient tolerance.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a structured, low-and-slow approach to administration, defining the required oral route and daily frequency. This protocol mandates a gradual titration phase and specifies necessary dose adjustments for certain patient populations, such as those with renal impairment, ensuring the medicine is introduced and maintained according to label-based principles.

Advertisements

Recent Clinical Evidence

Fosinopril Actavis: Recent Clinical Evidence


Research Evidence / Overview of Studies

Fosinopril Actavis, which contains the active ingredient fosinopril, belongs to a class of medicines known as Angiotensin-Converting Enzyme (ACE) inhibitors. Research on fosinopril has primarily focused on its use in managing hypertension (high blood pressure) and heart failure.

Early Phase Clinical Trials

Studies investigated the compound. Early research explored the compound's characteristics. Studies examined the activity of the compound. Research included laboratory investigation of the compound. These initial evaluations included investigations into appropriate dosage ranges for further study. Research evaluated the safety profile of the compound in adult populations.

Randomized Controlled Trials (RCTs)

A series of RCTs were performed to evaluate the compound against placebo. Research evaluated the compound using measures of blood pressure and inflammation markers. Some studies examined patient-reported symptoms after the compound was administered.

Key Efficacy Findings

Research examined the compound's role in initial use for hypertension. Comparative research has been conducted. Specific studies included assessment of physical function in individuals with heart failure. The results from individual trials varied. Some trials reported a statistically significant difference compared to placebo regarding blood pressure reduction, while others did not. The evidence remains mixed regarding the consistency of these findings across diverse patient groups.

Safety and Tolerability Profile

The most frequently reported events observed across the trials included gastrointestinal disturbances, headache, and fatigue. Research has evaluated the incidence and severity of these side effects. Serious adverse events were infrequent but included reports of hepatic (liver) and cardiovascular events. Studies and reviews have discussed the compound's metabolism and potential need for dose adjustment in individuals with renal (kidney) impairment.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Fosinopril Actavis (FAQ)

Q: How quickly does Fosinopril Actavis typically start working to lower blood pressure?

A: Official product information indicates that a blood pressure-lowering effect is generally observed within one hour after taking a single dose. The maximum blood pressure reduction typically occurs about 3 to 6 hours after administration. However, achieving the full, consistent benefit may require a treatment period of several weeks.


Q: Is Fosinopril Actavis the same type of medicine as Lisinopril or Enalapril?

A: Fosinopril Actavis is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. Medicines such as Lisinopril and Enalapril are also classified as ACE inhibitors. This indicates they share the same mechanism of action in affecting the body's natural system that regulates blood vessel narrowing.


Q: Why is Fosinopril Actavis sometimes used along with a diuretic (water pill)?

A: Fosinopril Actavis is sometimes used in combination with a diuretic to improve the therapeutic effect. Regulatory documents state that diuretics may be added if blood pressure control from fosinopril alone is inadequate. For managing heart failure, ACE inhibitors like fosinopril are often used as adjunctive therapy (an additional treatment) alongside diuretics.


Q: What is the full list of ingredients in Fosinopril Actavis tablets?

A: Fosinopril Actavis contains the active ingredient, fosinopril sodium. It also contains a number of inactive components called excipients to ensure the tablet is stable and delivered correctly. The complete list of both active and inactive ingredients can be found in the 'Description' or 'How Supplied' sections of the official regulatory drug label.


Q: How is Fosinopril Actavis eliminated from the body?

A: The active form of the medicine, fosinoprilat, is cleared from the body through a dual elimination route. It is removed almost equally by both the liver (hepatobiliary elimination) and the kidneys (renal excretion). This dual pathway is noted in the official pharmacokinetics section of the product information.


Q: Does Fosinopril Actavis interact with supplements or herbal products?

A: Regulatory documents explicitly warn about the use of potassium supplements and potassium-containing salt substitutes due to a potential increase in potassium levels (hyperkalemia). The product information states the importance of discussing all products, including supplements and herbal products, with a healthcare provider.


Q: Is Fosinopril Actavis a beta-blocker?

A: No. Fosinopril Actavis is classified as an Angiotensin-Converting Enzyme (ACE) inhibitor. This class of medicine works by blocking a specific enzyme in the body. Beta-blockers belong to a different drug class and function through a separate mechanism.


Q: Can Fosinopril Actavis affect a person's mood or cause depression?

A: Official adverse reaction lists include mood change and sleep disturbance as nervous system or psychiatric side effects that have been reported during clinical studies. Other effects like confusion and memory disturbance are also noted in the product information.


Q: How is the dose of Fosinopril Actavis usually adjusted by healthcare providers?

A: After starting the medicine, the dosage is adjusted based on the patient's blood pressure response. This evaluation is often performed by assessing blood pressure response shortly after dosing (peak) and near the end of the dosing interval (trough). If the blood pressure response is insufficient, adjustments may be considered by the healthcare provider.


Q: Why is blood pressure monitoring important when starting Fosinopril Actavis?

A: Monitoring is necessary, particularly at the beginning of treatment or after a change in dosage, to observe for signs of potentially significant hypotension (low blood pressure) or orthostasis (dizziness when standing up). Close medical supervision is specifically recommended after the initial dose for certain at-risk patients.


Q: Is Fosinopril Actavis a long-acting medicine?

A: Fosinopril Actavis is typically dosed once daily for both hypertension and heart failure. The active part of the medicine has an effective half-life of around 11.5 hours in hypertensive patients, indicating that the blood pressure-lowering effect is generally sustained throughout the 24-hour dosing period.


Q: What is the chemical structure of Fosinopril?

A: Official documents define Fosinopril sodium as a white to off-white crystalline powder with a specific chemical name: L-proline, 4-cyclohexyl-1-[[2-methyl-1-(1-oxopropoxy)propoxyphosphinyl]acetyl]-, sodium salt, trans-. This detailed chemical definition is provided in the 'Description' section of the regulatory label.


Q: Can Fosinopril Actavis cause weight gain or weight loss?

A: Official product information notes that appetite/weight change has been observed as a possible gastrointestinal side effect during clinical trials. Regulatory documents indicate that sudden weight gain can be monitored as it may relate to fluid retention or changes in kidney function.


Q: What is the half-life of Fosinopril after I take it?

A: The effective half-life describes the duration of the active substance in the body. For the active metabolite, fosinoprilat, the effective half-life averages 11.5 hours in patients treated for high blood pressure and 14 hours in patients treated for heart failure.

Advertisements

How should Fosinopril Actavis be stored and disposed of?

Fosinopril sodium tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be protected from both moisture and light and should be stored away from heat.

Storage Requirements

The tablets must not be frozen and must remain in the original, closed container to maintain stability. For safety, the product is required to be kept out of the reach of children.

Disposal

Disposal of any unused or expired Fosinopril Actavis must follow the guidance of a healthcare professional and be carried out in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fosinopril Actavis found in:

A-Z Index: